Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Dihydrofolate reductase | 0.1054 | 1 | 0.5 |
Onchocerca volvulus | 0.0057 | 0 | 0.5 | |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0403 | 0.3471 | 0.5 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.1054 | 1 | 1 |
Trypanosoma brucei | pteridine reductase 1 | 0.1013 | 0.9591 | 1 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0403 | 0.3471 | 1 |
Echinococcus granulosus | dihydrofolate reductase | 0.1054 | 1 | 0.5 |
Leishmania major | pteridine reductase 1 | 0.1027 | 0.9726 | 1 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.1054 | 1 | 0.5 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.1054 | 1 | 0.5 |
Echinococcus multilocularis | dihydrofolate reductase | 0.1054 | 1 | 0.5 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0403 | 0.3471 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0403 | 0.3471 | 1 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0403 | 0.3471 | 0.3568 |
Schistosoma mansoni | dihydrofolate reductase | 0.1054 | 1 | 0.5 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0403 | 0.3471 | 0.3618 |
Chlamydia trachomatis | dihydrofolate reductase | 0.1054 | 1 | 0.5 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.1054 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 8.2753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (binding) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.